Get the Stockscreener App
24.42
0.41%
0.10
Arrivent Biopharma Inc stock is traded at $24.42, with a volume of 209.77K.
It is up +0.41% in the last 24 hours and up +20.89% over the past month.
ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize the team's deep drug development experience to maximize the potential of the lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody-drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.
See More
Previous Close:
$24.32
Open:
$24.36
24h Volume:
209.77K
Relative Volume:
0.60
Market Cap:
$1.01B
Revenue:
-
Net Income/Loss:
$-136.98M
P/E Ratio:
-6.0746
EPS:
-4.02
Net Cash Flow:
$-126.63M
1W Performance:
-1.09%
1M Performance:
+20.89%
6M Performance:
+3.34%
1Y Performance:
-5.64%
1-Day Range:
$23.52
$24.78
1-Week Range:
$23.29
$25.82
52-Week Range:
$15.47
$29.71
Arrivent Biopharma Inc Stock (AVBP) Company Profile
Name
Arrivent Biopharma Inc
Sector
Industry
Phone
240-780-6356
Address
18 CAMPUS BLVD., NEWTOWN SQUARE
Compare AVBP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AVBP
Arrivent Biopharma Inc
|
24.42 | 1.00B | 0 | -136.98M | -126.63M | -4.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Arrivent Biopharma Inc Stock (AVBP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-10-25 | Initiated | BTIG Research | Buy |
| Nov-25-25 | Initiated | Truist | Buy |
| Jul-10-25 | Resumed | Goldman | Buy |
| Mar-20-25 | Initiated | B. Riley Securities | Buy |
| Mar-10-25 | Initiated | Guggenheim | Buy |
| Jul-22-24 | Initiated | Oppenheimer | Outperform |
| Apr-30-24 | Initiated | H.C. Wainwright | Buy |
| Feb-20-24 | Initiated | Citigroup | Buy |
| Feb-20-24 | Initiated | Goldman | Buy |
| Feb-20-24 | Initiated | Jefferies | Buy |
View All
Arrivent Biopharma Inc Stock (AVBP) Latest News
Fund 1 Investments LLC Acquires New Position in ArriVent BioPharma, Inc. $AVBP - MarketBeat
BTIG Research Begins Coverage on ArriVent BioPharma (NASDAQ:AVBP) - Defense World
ArriVent BioPharma Inc (AVBP) is looking forward to a strong quarter - setenews.com
ArriVent BioPharma (NASDAQ:AVBP) Coverage Initiated at BTIG Research - MarketBeat
ArriVent BioPharma stock initiated with Buy rating at BTIG on oncology potential - Investing.com Canada
ArriVent Biopharma initiated with a Buy at BTIG - TipRanks
ArriVent Biopharma initiated with a Buy at BTIG on firmonertinib potential - TipRanks
BTIG Initiates ArriVent BioPharma at Buy With $45 Price Target - marketscreener.com
ArriVent BioPharma (NASDAQ:AVBP) versus Sunshine Biopharma (NASDAQ:SBFM) Critical Review - Defense World
Buy Rating for ArriVent BioPharma, Inc. Driven by Promising Developments in EGFR Exon 20 NSCLC Treatment - TipRanks
Is ArriVent BioPharma Inc (AVBP) positioned for future growth? - Setenews
Buy Rating for ArriVent BioPharma Driven by Promising Firmonertinib Trial Results - TipRanks
ArriVent BioPharma (NASDAQ:AVBP) Shares Down 6.4%Here's What Happened - MarketBeat
Understanding Momentum Shifts in (AVBP) - news.stocktradersdaily.com
How ArriVent BioPharma Inc. stock trades before earnings2025 Trading Volume Trends & Accurate Trade Setup Notifications - Newser
Will ArriVent BioPharma Inc. stock sustain high P E ratiosWeekly Market Outlook & Stepwise Trade Signal Implementation - Newser
A new trading data show ArriVent BioPharma Inc (AVBP) is showing positive returns. - Setenews
ArriVent BioPharma (NASDAQ:AVBP) Coverage Initiated at Truist Financial - MarketBeat
Truist Financial Initiates Coverage on ArriVent BioPharma (NASDAQ:AVBP) - Defense World
ArriVent Biopharma initiated with a Buy at Truist - TipRanks
ArriVent BioPharma stock initiated with Buy rating at Truist on lung cancer drug - Investing.com Canada
Truist Initiates ArriVent BioPharma at Buy With $43 Price Target - marketscreener.com
AXQ Capital LP Buys New Position in Intellia Therapeutics, Inc. $NTLA - Defense World
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
Avoiding Lag: Real-Time Signals in (AVBP) Movement - news.stocktradersdaily.com
ArriVent Maps Ambitious 2026 Oncology Push as Firmonertinib Program Gains Steam - MSN
Is ArriVent BioPharma Inc. stock in correction or buying zoneCEO Change & Smart Money Movement Alerts - newser.com
Can ArriVent BioPharma Inc. stock outperform in 2025 bull marketEarnings Overview Summary & Momentum Based Trading Signals - newser.com
Best data tools to analyze ArriVent BioPharma Inc. stockJuly 2025 Big Picture & Smart Swing Trading Alerts - newser.com
How institutional ownership impacts ArriVent BioPharma Inc. stockWeekly Trade Recap & Stepwise Entry and Exit Trade Signals - newser.com
Will ArriVent BioPharma Inc. stock gain from lower inflationWeekly Profit Recap & Reliable Volume Spike Trade Alerts - newser.com
How ArriVent BioPharma Inc. stock reacts to Fed rate cutsGap Down & High Yield Equity Trading Tips - newser.com
Can momentum traders help lift ArriVent BioPharma Inc.Portfolio Value Summary & AI Forecasted Stock Moves - newser.com
Published on: 2025-11-19 02:02:03 - newser.com
Is ArriVent BioPharma Inc. stock a defensive play in 20252025 Volatility Report & Real-Time Chart Pattern Alerts - newser.com
Why Red River Bancshares, Inc. stock attracts strong analyst attention - newser.com
Evaluating ArriVent BioPharma Inc. with trendline analysisWeekly Risk Summary & Free Real-Time Market Sentiment Alerts - newser.com
Analyzing ArriVent BioPharma Inc. with risk reward ratio chartsJuly 2025 Decliners & Growth Oriented Trading Recommendations - newser.com
Published on: 2025-11-15 15:01:05 - newser.com
Why ArriVent BioPharma Inc. stock is favored by pension fundsLong Setup & Accurate Entry/Exit Alerts - newser.com
Momentum divergence signals in ArriVent BioPharma Inc. chartWeekly Stock Recap & Real-Time Volume Analysis - newser.com
What is the fair value of ArriVent BioPharma Inc. stock now2025 Earnings Impact & Fast Gain Stock Tips - Fundação Cultural do Pará
What is HC Wainwright’s Forecast for AVBP FY2025 Earnings? - Defense World
Arrivent Biopharma Inc Stock (AVBP) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):